Search | Clinical Trials Finder

Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Renal Impairment
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Healthy Volunteers
Interventions: Fedratinib, Fluconazole; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hematopoietic Neoplasm
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 16
States / cities: Phoenix, Arizona • San Francisco, California • Atlanta, Georgia + 10 more

Conditions: Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Decitabine, Ruxolitinib, Fedratinib, Questionnaire Administration, Pacritinib, Biospecimen Collection; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteers
Interventions: Fedratinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Fedratinib, Rifampin, Efavirenz; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: Fedratinib, Digoxin, Rosuvastatin, Metformin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Revumenib, Ruxolitinib, FEDRATINIB, Momelotinib; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Myeloproliferative Neoplasm
Interventions: Fedratinib Pill; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hematopoietic Neoplasm
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Hepatic Impairment
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions: itacitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more

Conditions: Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS
Interventions: Fedratinib Pill; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Tampa, Florida • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Myelofibrosis
Interventions: SAR302503 (TG101348); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: La Jolla, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Myelofibrosis
Interventions: TG101348; Drug
Lead sponsor: TargeGen; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: San Diego, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Neoplasm Malignant
Interventions: SAR302503 (TG101348), Placebo SAR302503, Panolosetron; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Detroit, Michigan + 4 more

Conditions: Myelofibrosis
Interventions: BMS-986158, Ruxolitinib, Fedratinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 8
States / cities: Newport Beach, California • Lake Mary, Florida • New Orleans, Louisiana + 5 more

Conditions: Hematopoietic Neoplasm
Interventions: SAR302503, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: FEDRATINIB; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more

Conditions: Myelofibrosis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Solid Tumor
Interventions: SAR302503, omeprazol, metoprolol, midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Augusta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Myelofibrosis
Interventions: Selinexor, Physician's Choice Treatment; Drug · Other
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Pasadena, California • Aurora, Colorado • Niles, Illinois + 1 more

Conditions: Myeloproliferative Neoplasm
Interventions: Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg; Drug
Lead sponsor: Joseph Jurcic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Revumenib in Patients With Myelofibrosis

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)